James George Chopas - 12 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: VP/Chief Accounting Officer
Signature: /s/ David Watson, attorney-in-fact for James Chopas
Issuer symbol: APLS
Transactions as of: 12 Jan 2023
Net transactions value: +$795,903
Form type: 4
Filing time: 17 Jan 2023, 18:26:38 UTC
Previous filing: 24 Oct 2022
Next filing: 24 Jan 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Award	$0	+9,621	+52%	$0.000000	28,072	12 Jan 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Award	$795,903	+15,114		$52.66	15,114	12 Jan 2023	Common Stock	15,114	$52.66	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.
F2	This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.